Journal of Bioequivalence & Bioavailability

Ericka López-Bojórquez

Publications

• Research Article
  Bioavailability of Two Different Tablet Formulations of Telmisartan of Two Different Strengths (40 mg and 80 mg) in Healthy Male Mexican Volunteers
  Author(s): Daniel Ponce-Navarrete, Armando Cortés-Mendoza, Ericka López-Bojórquez, Jessica González-Bañuelos, Victoria Burke-Fraga and Mario González-de la ParraDaniel Ponce-Navarrete, Armando Cortés-Mendoza, Ericka López-Bojórquez, Jessica González-Bañuelos, Victoria Burke-Fraga and Mario González-de la Parra
  
  Telmisartan is a non-peptide angiotensin II receptor antagonist. In Mexico, it is indicated for the treatment of arterial hypertension and for the prevention of morbidity and mortality of patients ≥ 55 years old with high risk of cardiovascular disease. The aim of these two studies was to compare the bioavailability and to determine the bioequivalence of two test formulations containing 40 mg and 80 mg of oral telmisartan. Two separate, singledose, single-blind, randomized, two-period, crossover studies were conducted. For each study a different set of 30 male subjects completed both studies with a 14-day washout period. In both studies, the study formulations were administered after a 10-hour overnight fast. For pharmacokinetic analysis, blood samples were drawn at baseline, 0.25, 0.5, 0.75, 1, 1.33, 1.67, 2, 3, 4, 6, 8, 12, 24, 48 and 72 hours after administration. Plasma concent.. View More»
  DOI: 10.4172/jbb.1000233

  Abstract PDF